Congo to use Ebola vaccine to counter flare-up

Four people have tested positive for Ebola


Democratic Republic of Congo (DRC) officials say they will start using Ebola vaccine to counter a flare-up in the heavily populated eastern part of the Central African country, according to an article on the Reuters website.

Four people have tested positive for Ebola in and around Mangina, a town of about 60,000 people in North Kivu province, about 60 miles) from the Ugandan border.  

Another 20 people died from unidentified hemorrhagic fevers in July. The World Health Organization (WHO) declared the ninth outbreak of Ebola in the Democratic Republic of the Congo (DRC) over on July 24, according to an article on WHO website. 

Unlike previous DRC Ebola outbreaks, this one involved four locations, including an urban center with river connections to the capital and to neighboring countries, as well as remote rainforest villages.

Read the article.

 

 



August 7, 2018


Topic Area: Infection Control


Recent Posts

Seeking Standards for Microbial Loads in Healthcare Facilities

Why is there no binding standard for the acceptable microbial load on surfaces or in the air in hospitals?


UCR Health Unveils Plans for Major Expansion

The vision for the site will include an outpatient diagnostic center and possible future expansion.


High-Performance Windows Support Safety at UW Medicine's New Behavioral Health Center

Case study: Engineered for strength, quiet and daylight, the chosen windows help create a safe, calming and energy-efficient environment for patients and providers.


Central Maine Healthcare Dealing with IT System Outage

The organization identified unusual activity within their computer software, prompting them to secure and shut off all IT systems.


Kaiser Permanente Opens Newly Expanded Everett Medical Center

The facility offers primary care and pediatric care and has specialty care departments.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.